宫颈癌患者血清 miRNA-18a、CXCL10的表达及预后价值

Expression and prognostic value of serum miR-18a and CXCL10 in patients with cervical cancer

摘要

目的 探讨宫颈癌患者血清微小 RNA-18a(miR-18a)、CXC 趋化因子配体10(CXCL10)的表达及对预后的评估价值。方法 回顾性选取2017年1月至2020年12月中国人民解放军中部战区总医院收治的112例宫颈癌患者为病例组,并根据患者3年生存情况分为生存组和死亡组.另收集83例宫颈良性肿瘤患者为良性组.检测各组血清 miR-18a、CXCL10水平,分析血 miR-18a、CXCL10水平与宫颈癌临床特征及患者生存预后的相关性。结果 癌症组患者血清 miR-18a、CXCL10水平明显高于良性组(t=13.819、17.524,P<0.05).病例组中肌层浸润深度>1/2、TNM 分级Ⅲ~Ⅳ期、淋巴结转移患者的血清 miR-18a及CXCL10水平更高(t=2.260、4.118、3.851、2.141、3.104、2.699,P<0.05).死亡组患者 TNM 分级Ⅲ~Ⅳ期、淋巴结转移发生率明显高于生存组(χ²=17.903、36.107,P<0.05),死亡组中血清 miR-18a、CXCL10水平明显高于生存组(t=6.359、5.373,P<0.05).COX 多因素回归分析显示 TNM 分级、淋巴结转移、血 miR-18a和 CXCL10水平升高为宫颈癌患者预后不良的危险因素(OR=5.778、5.150、1.220、1.020,P<0.05).血清 miR-18a联合 CXCL10检测宫颈癌患者生存预后的曲线下面积为0.887(95%CI:0.827~0.948)。结论 宫颈癌患者血清 miR-18a、CXCL10水平明显升高,血清 miR-18a、CXCL10及肿瘤分期、淋巴结转移和生存预后密切相关.

Abstract

Objective To investigate the expression of serum microRNA-18a (miR-18a) and CXC chemokine ligand 10 (CXCL10) in patients with cervical cancer and their value in evaluating prognosis. Methods 112 patients with cervical cancer who were admitted to the Central War Zone General Hospital of the People's Liberation Army of China from January 2017 to December 2020 were retrospectively selected as the case group, and were divided into the survival group and the death group based on their 3-year survival status. In addition, 83 patients with benign cervical tumors were included in the benign group. Serum levels of miR-18a and CXCL10 were measured in each group, and their correlation with cervical cancer clinical characteristics and patient survival prognosis was analyzed. Results The serum levels of miR-18a and CXCL10 in the cancer group were significantly higher than those in the benign group (t=13.819 and 17.524, respectively, P<0.05). In the case group, the serum levels of miR-18a and CXCL10 were higher in patients with a depth of myometrial invasion >1/2, TNM stage Ⅲ to Ⅳ, lymph node metastasis (t=2.260, 4.118, 3.851, 2.141, 3.104 and 2.699, respectively, P<0.05). The incidence of TNM stage Ⅲ to Ⅳ and lymph node metastasis was significantly higher in the death group compared to the survival group (χ²=17.903 and 36.107, respectively, P<0.05), and the levels of serum miR-18a and CXCL10 in the death group were significantly higher than those in the survival group (t=6.359 and 5.373, respectively, P<0.05). COX multivariate regression analysis showed that TNM grade, lymph node metastasis, and increased levels of miR-18a and CXCL10 were risk factors for poor prognosis in patients with cervical cancer (OR=5.778, 5.150, 1.220 and 1.020, respectively, P<0.05). The area under the curve (AUC) for the combined detection of serum miR-18a and CXCL10 in predicting the survival prognosis of cervical cancer patients was 0.887 (95%CI: 0.827 to 0.948). Conclusion The levels of serum miR-18a and CXCL10 are significantly increased in patients with cervical cancer, and the serum levels of miR-18a and CXCL10 are closely related to tumor stage, lymph node metastasis and survival prognosis.

关键词

宫颈癌 / 微小 RNA-18a / CXC趋化因子配体 / 临床特征 / 生存预后

Key words

cervical cancer / microRNA-18a / CXC chemokine ligand / clinical characteristic / survival prognosis

参考文献

[1] 蔡会龙, 原伟光, 孙惠昕. 全球及我国宫颈癌流行现状及防治策略[J]. 临床肿瘤学杂志, 2023, 28(1): 90-93.

[2] Smith A J B, Beavis A L, Rositch A F, et al. Disparities in diagnosis and treatment of cervical adenocarcinoma compared with squamous cell carcinoma: an analysis of the national cancer database, 2004-2017[J]. J Low Genit Tract Dis, 2023, 27(1): 29-34.

[3] Schubert M, Bauerschlag D O, Muallem M Z, et al. Challenges in the diagnosis and individualized treatment of cervical cancer[J]. Medicina (Kaunas), 2023, 59(5): 925.

[4] Yun J H, Baek M J, Jung H I. Expression of miR-221 and miR-18a in patients with hepatocellular carcinoma and its clinical significance[J]. Korean J Clin Oncol, 2022, 18(1): 17-26.

[5] Sun Y, Mo Y, Jiang S, et al. CXC chemokine ligand-10 promotes the accumulation of monocyte-like myeloid-derived suppressor cells by activating p38 MAPK signaling under tumor conditions[J]. Cancer Sci, 2023, 114(1): 142-151.

[6] 中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489.

[7] 努尔比亚·阿布拉, 派尔旦木·那斯, 祖米然·热西提尔, 等. 喀什地区妇女宫颈癌预防认知现状及综合性健康教育干预效果[J]. 中国妇幼健康研究, 2023, 34(9): 47-51.

[8] Cohen C M, Wentzensen N, Castle P E, et al. Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype[J]. J Clin Oncol, 2023, 41(5): 1059-1068.

[9] 丁松瑞, 李政, 赵敏, 等. 云南省汉族宫颈癌患者发病因素病例对照研究[J]. 中国妇幼健康研究, 2022, 33(9): 97-102.

[10] 李聪, 王燕, 吴淑娟. 血清黏蛋白-1、胸苷激酶1水平与早期宫颈癌患者预后的关系[J]. 中国临床医生杂志, 2021, 49(11): 1361-1364.

[11] Swanson A A, Pantanowitz L. The evolution of cervical cancer screening[J]. J Am Soc Cytopathol, 2024, 13(1): 10-15.

[12] Wang Y, Yang J, Wang Y. Serum miRNA combined with transvaginal color doppler ultrasound diagnosis clinical research on cervical cancer[J]. J Ultrasound Med, 2024, 43(4): 791-798.

[13] Egeland N G, Jonsdottir K, Aure M R, et al. MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers[J]. BMC Cancer, 2020, 20(1): 377.

[14] Franz C, Jötten L, Wührl M, et al. Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment[J]. Cancer Rep (Hoboken), 2023, 6(12): e1899.

[15] Nair M G, D A, M C, et al. MiR-18a mediates immune evasion in ER-positive breast cancer through Wnt signaling[J]. Cells, 2022, 11(10): 1672.

[16] 李丹萍, 李宗民, 张丽峡, 等. 血清 miR-18a、miR-485-5p对 HPV 阳性宫颈癌的诊断价值[J]. 中华全科医学, 2023, 21(2): 263-266.

[17] Zhang J, Dong D, Wei Q, et al. CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma[J]. BMC Cancer, 2022, 22(1): 1052.

[18] Shang S, Yang Y W, Chen F, et al. TRIB3 reduces CD8⁺ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer [J]. Sci Transl Med, 2022, 14(626): eabf0992.

[19] Limagne E, Nuttin L, Thibaudin M, et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells[J]. Cancer Cell, 2022, 40(2): 136-152.e12.